Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity

被引:0
作者
Minh Ngoc Duong
Aurore Cleret
Eva-Laure Matera
Kamel Chettab
Doriane Mathé
Sandrine Valsesia-Wittmann
Béatrice Clémenceau
Charles Dumontet
机构
[1] Centre de Recherche en Cancérologie de Lyon (CRCL),
[2] INSERM UMR 1052,undefined
[3] CNRS 5286,undefined
[4] Centre Léon Bérard,undefined
[5] Pôle des sciences cliniques,undefined
[6] Plateforme d’innovations en immunomonitoring et immunothérapie,undefined
[7] INSERM U892,undefined
[8] Centre de Recherche en Cancérologie Nantes-Angers,undefined
[9] Centre Hospitalier Universitaire de Nantes,undefined
[10] Hospices Civils de Lyon,undefined
来源
Breast Cancer Research | / 17卷
关键词
Natural Killer Cell; Trastuzumab; Conditioned Medium; Lipoma; Adipose Cell;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 215 条
[1]  
Ross JS(2009)The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320-68
[2]  
Slodkowska EA(2007)Trastuzumab—mechanism of action and use in clinical practice N Engl J Med 357 39-51
[3]  
Symmans WF(2008)Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ J Clin Oncol 26 1789-96
[4]  
Pusztai L(2010)–positive metastatic breast cancer Cancer Cell 18 160-70
[5]  
Ravdin PM(2006)The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity Breast Cancer Res 8 215-27
[6]  
Hortobagyi GN(2004)HER2 therapy: Molecular mechanisms of trastuzumab resistance Cancer Cell 6 117-9
[7]  
Hudis CA(1997)PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Int J Cancer 73 875-24
[8]  
Musolino A(2004)Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells Clin Cancer Res 10 1618-91
[9]  
Naldi N(2002)Monitoring of serum Her-2/ Int J Cancer 99 783-93
[10]  
Bortesi B(2012) predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer Breast Cancer Res Treat 134 583-7